The relevance here is strategy.
RedHill's Phase 2/3 COVID-19 Study of Opaganib completes in March 2021. My previous post was their Phase 2 results. If the COVID-19 results are positive then Opaganib will be approved before the end of the year.
Now the trick here is quite a clever one commonly used by pharma companies. If RedHill gets a positive readout in their prostate cancer trial, they simply apply for a label extension. The question now becomes will they be able to apply for this approval in a way that shuts out Veyonda from being approved for treating late-state prostate cancer. And the answer is yes, there is a way. They may be considered biosimilars and late-stage prostate cancer is an unmet condition after all.
Redhill's prostate cancer trial reads out in 2022, before the DARRT-2 trial. It's a smart strategy. You shouldn't underestimate a company like Redhill Biopharma, if you look at their pipeline for Opaganib it is clear they are directly challenging Noxopharm.
- Forums
- ASX - By Stock
- Competitors
The relevance here is strategy. RedHill's Phase 2/3 COVID-19...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M |
Open | High | Low | Value | Volume |
12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6612 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 99714 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6612 | 0.115 |
6 | 681590 | 0.110 |
5 | 132523 | 0.105 |
5 | 532405 | 0.100 |
1 | 25357 | 0.098 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 99714 | 1 |
0.125 | 261572 | 5 |
0.130 | 134000 | 3 |
0.135 | 361881 | 5 |
0.140 | 241192 | 9 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |